Eir Ventures, a Stockholm, and Copenhagen, Denmark-based life science venture firm, held the first close of its new fund of EUR76m.
The fund is launched with support from an investor syndicate comprising Saminvest, the European Investment Fund (EIF), Vækstfonden, Novo Holdings, as well as additional private investors.
Launched by a team of life science investors including Managing Partners Dr Magnus Persson, Stephan Christgau, Andreas Segerros, and Special Partner Amanda Hayward, Eir Ventures will invest in innovative companies with products and technologies addressing significant unmet medical need and a potential to improve the life of patients.
The fund will invest in high return potential opportunities in the Nordics, Europe and the US, with a particular focus on innovations from the leading universities and incubators in the Nordics. It has established collaborations with select Nordic Universities.